Inclusion Criteria:

•Signed and dated written informed consent
•Male or females ≥ 40 years of age
•Established clinical history of COPD by ATS/ERS definition
•Females are eligible to enter and participate if of non-childbearing potential, or if of child bearing potential, has a negative serum pregnancy test at screening, and agrees to one of the acceptable contraceptive methods listed in protocol, used consistently and correctly
•Former or current smoker > 10 pack years
•Post-albuterol spirometry criteria: FEV1/FVC ratio ≤ 0.70 and FEV1 ≤ 70% of predicted normal (NHANES III)
-have been hospitalised or have been treated with oral corticosteroids or antibiotics for their COPD within the last 3 years prior to Screening (Visit 1)

Exclusion Criteria:

•Current diagnosis of asthma
•Subjects with other respiratory disorders including active tuberculosis, α1-antitrypsin deficiency, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases
•Lung volume reduction surgery within previous 12 months
•Clinically significant abnormalities not due to COPD by chest x-ray
•Hospitalized for poorly controlled COPD within 12 weeks of Screening
•Poorly controlled COPD 6 weeks prior to Screening, defined as acute worsening of COPD that is managed by the subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician
•Lower respiratory infection requiring antibiotics 6 weeks prior to Screening
•Uncontrolled or clinically significant (in opinion of PI) cardiovascular, hypertension, neurological, psychiatric, renal, hepatic, immunological, endocrine, peptic ulcer disease, or hematological abnormalities
•Carcinoma not in complete remission for at least 5 years
•Subjects with history of hypersensitivity to study medications (e.g., beta-agonists, corticosteroid) or components of inhalation powder (e.g., lactose, magnesium stearate)
•Subjects with history of severe milk protein allergy that, in opinion of study physician, contraindicates subject’s participation
• Known/suspected history of alcohol or drug abuse in the last 2 years
•Women who are pregnant or lactating or plan to become pregnant
•Subjects medically unable to withhold albuterol and/or ipratropium 4 hours prior to spirometry testing at each study visit
•Use of certain medications such as bronchodilators and corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator will discuss the specific medications)
•Long Term Oxygen Therapy (LTOT) or nocturnal oxygen therapy >12 hours a day
•Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Screening or during the study
• Non-compliance or inability to comply with study procedures or scheduled visits
•Affiliation with investigator site

• Spain (click to view all sites in Spain)
• GSK Investigational Site
  San Sebastián, 20014; COMPLETED;
  Contact: Javier Laparra Galíndez, Principal Investigator, .
• GSK Investigational Site
  Barakaldo (Vizcaya), 48903; COMPLETED;
  Contact: Juan Bautista Gáldiz Iturri, Principal Investigator, .
• GSK Investigational Site
  Cáceres, 10003; COMPLETED;
  Contact: Javier Gómez De Terreros Caro, Principal Investigator, .
• GSK Investigational Site
  Pozuelo de Alarcón/Madrid, 28223; COMPLETED;
  Contact: José Maria Echave-Sustaeta, Principal Investigator, .
• GSK Investigational Site
  Madrid, 28040; RECRUITING;
  Contact: José Luis Álvarez-Sala Walther, Principal Investigator, .
• GSK Investigational Site
  Valencia, 46015; COMPLETED;
  Contact: Pedro José Cordero Rodríguez, Principal Investigator, .